

## Leukaemia Section

### Short Communication

# t(1;14)(p35;q32) LAPT<sub>M5</sub>/IGH

Jean Loup Huret

R.M. Gorbacheva Memorial Institute of Children Oncology, Hematology and Transplantation at Pavlov First Saint-Petersburg State Medical University, Saint-Petersburg, Russian Federation / e-mail: [tatgindina@gmail.com](mailto:tatgindina@gmail.com)

Published in Atlas Database: October 2019

Online updated version : <http://AtlasGeneticsOncology.org/Anomalies/t0114p35q32LAPT<sub>M5</sub>-IGHID1486.html>

Printable original version : <http://documents.irevues.inist.fr/bitstream/handle/2042/70776/10-2019-t0114p35q32LAPT<sub>M5</sub>-IGHID1486.pdf>  
DOI: 10.4267/2042/70776

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence.  
© 2020 Atlas of Genetics and Cytogenetics in Oncology and Haematology

## Abstract

Review on t(1;14)(p35;q32), with data on clinics, and the genes involved.

### Keywords

Chromosome 1; chromosome 14; LAPT<sub>M5</sub>; IGH; Mature B-cell neoplasms

## Clinics and pathology

### Disease

Mature B-cell neoplasms

### Epidemiology

A t(1;14)(p35;q32) LAPT<sub>M5</sub>/IGH was found in a multiple myeloma cell line (Hayami et al., 2003). Two other cases of t(1;14)(p35;q32), but without gene assessment were described: a male patient, with Binet stage 1 chronic lymphocytic leukemia (CLL), and with mutated NOTCH1 (Giudice et al., 2018), and a female aged 55-year old female patient with follicular lymphoma (Slavutsky et al., 1987).

## Genetics

To be noted is that a PHC2 (1p35.1) / HSP90AA1 (14q32.31) fusion was found in prostate cancer (Yoshihara et al., 2015) and a PPP2R5C (14q32.31) / CCDC28B (1p35.2) fusion in hepatocellular

carcinoma (Hu et al., 2018), data extracted from <http://atlasgeneticsoncology.org/Bands/1p35.html>.

## Genes involved and proteins

### LAPT<sub>M5</sub> (lysosomal protein transmembrane 5)

#### Location

1p35.2

#### Protein

262 amino acids, contains 5 trans-membrane helices. Membrane protein that localizes to intracellular vesicles, lysosomes in particular. LAPT<sub>M5</sub> may play an important role as a negative regulator of T cell or B cell receptor-mediated signaling.

Overexpression of LAPT<sub>M5</sub> induces lysosomal cell death. LAPT<sub>M5</sub> transcription is often decreased in various types of cancer cell lines, in non-small cell lung cancer and esophageal squamous cell carcinoma tumors.

Low expression is associated with poor prognosis. LAPT<sub>M5</sub> functions as a tumor suppressor (Nuylan et al., 2016).

### IGH (Immunoglobulin Heavy)

#### Location

14q32.33

## Result of the chromosomal anomaly

## Hybrid gene

### Description

The rearrangement occurred between the switch region of IGH and the first intron of LAPTM5. LAPTM5 was interrupted within its coding region and was not expressed (Hayami et al., 2003).

### Fusion protein

#### Oncogenesis

Inactivation of LAPTM5

## References

Slavutsky I, Labal de Vinuesa M, Estévez ME, Sen L, Dupont J, Larripa I. Chromosome studies in human hematologic diseases: non-Hodgkin's lymphomas. *Haematologica*. 1987 Jan-Feb;72(1):29-37

Giudice ID, Rigolin GM, Raponi S, Cafforio L, Ilari C, Wang J, Bordyuh M, Picicocchi A, Marinelli M, Nanni M, Tavolaro S, Filetti M, Bardi A, Tammiso E, Volta E, Negrini M, Saccetti E, Mauro FR, Rossi D, Gaidano G, Guarini A, Rabadan R, Cuneo A, Foà R. Refined karyotype-based prognostic stratification of chronic lymphocytic leukemia with a low- and very-low-risk genetic profile. *Leukemia*. 2018 Feb;32(2):543-546

Yoshihara K, Wang Q, Torres-Garcia W, Zheng S, Vegesna R, Kim H, Verhaak RG. The landscape and therapeutic relevance of cancer-associated transcript fusions. *Oncogene*. 2015 Sep 10;34(37):4845-54

Hayami Y, Iida S, Nakazawa N, Hanamura I, Kato M, Komatsu H, Miura I, Dave BJ, Sanger WG, Lim B, Taniwaki M, Ueda R. Inactivation of the E3/LAPTM5 gene by chromosomal rearrangement and DNA methylation in human multiple myeloma. *Leukemia*. 2003 Aug;17(8):1650-7

Nuylan M, Kawano T, Inazawa J, Inoue J.. Down-regulation of LAPTM5 in human cancer cells. *Oncotarget*. 2016 May 10;7(19):28320-8. doi: 10.18632/oncotarget.8614.

Hu X, Wang Q, Tang M, Barthel F, Amin S, Yoshihara K, Lang FM, Martinez-Ledesma E, Lee SH, Zheng S, Verhaak RGW.. TumorFusions: an integrative resource for cancer-associated transcript fusions. *Nucleic Acids Res*. 2018 Jan 4;46(D1):D1144-D1149. doi: 10.1093/nar/gkx1018.

---

*This article should be referenced as such:*

Huret JL. t(1;14)(p35;q32) LAPTM5/IGH. *Atlas Genet Cytogenet Oncol Haematol*. 2020; 24(8): 314-314.

---